Replies to post #224761 on Biotech Values

[DewDiligence]

GILD’s (second) Selonsertib phase-3 failure in NASH—this time in F3-fibrosis patients:

https://finance.yahoo.com/news/gileads-nash-drug-fails-meet-124021920.html

https://finance.yahoo.com/news/gilead-announces-topline-data-phase-120000952.html